An in vivo study by Karthikeyan et al. confirmed that CDH6 was inhibited by mutant p53 in high-grade serous ovarian cancer, which suggests that CDH6 may be a biomarker for this condition29. Here, TP53 is linked to ovarian serous adenocarcinoma.